miltefosine has been researched along with Carcinoma in 4 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| " In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg." | 1.27 | Alkyl phosphocholines: toxicity and anticancer properties. ( Berger, MR; Eibl, HJ; Garzon, FT; Muschiol, C; Scherf, HR; Schmähl, D; Schuler, B; Unger, C; Zeller, WJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Schönenberger, H | 1 |
| Engel, J | 1 |
| Clive, S | 1 |
| Gardiner, J | 1 |
| Leonard, RC | 1 |
| Naundorf, H | 1 |
| Rewasowa, EC | 1 |
| Fichtner, I | 1 |
| Büttner, B | 1 |
| Becker, M | 1 |
| Görlich, M | 1 |
| Muschiol, C | 1 |
| Berger, MR | 1 |
| Schuler, B | 1 |
| Scherf, HR | 1 |
| Garzon, FT | 1 |
| Zeller, WJ | 1 |
| Unger, C | 1 |
| Eibl, HJ | 1 |
| Schmähl, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for miltefosine and Carcinoma
| Article | Year |
|---|---|
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
3 other studies available for miltefosine and Carcinoma
| Article | Year |
|---|---|
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug | 1993 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A | 1992 |
Alkyl phosphocholines: toxicity and anticancer properties.
Topics: Animals; Antineoplastic Agents; Carcinoma; Choline; Dose-Response Relationship, Drug; Female; Male; | 1987 |